The oncology community is gearing up for the largest gathering of the year, the American Society of Clinical Oncology Annual Meeting (ASCO), which will take place June 3-7 in Chicago. The meeting is a critically important annual gathering of thousands of experts where the latest scientific breakthroughs and exciting advances in the treatment of cancer are discussed.
Foundation Medicine and its collaborators continue to lead the advancement of comprehensive genomic profiling (CGP) and the important role it plays in advancing precision medicine in cancer care – enabling more informed treatment strategies for physicians and potentially improved outcomes for patients. At this year’s meeting, we will present a robust scientific schedule, including two oral presentations, six poster discussions and nineteen posters. We’ll also have a sizable presence on the exhibition hall floor (booth #24109) where meeting attendees can learn about our end-to-end molecular information products and solutions.
The data being presented will highlight the important role of CGP across broad tumor types, and its potential link to improving cancer care. Specifically, these data will include identification of new therapeutic treatment options, the ability to potentially determine predictors of therapeutic response to treatment in several cancer types, and the role of CGP in advancing the collective understanding of immune-based treatment approaches and their potential effectiveness in targeting certain cancer cell profiles.
These studies build on the growing body of evidence supporting cancer as a disease of the genome. As an informed cancer community, we have a collective imperative to shift the way we think about cancer treatment and consider comprehensive genomic profiling as a key step in the clinical course of care for patients.
For specifics about our presentation schedule at ASCO, please see our press release. For more Foundation Medicine ASCO news, follow us on Twitter (@FoundationATCG) and LinkedIn throughout the conference.